A new treatment and updated clinical practice guidelines for MASLD

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-11-11 DOI:10.1038/s41575-024-01014-y

Elizabeth E. Powell

引用次数: 0

Abstract

The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatohepatitis, updated guidelines on the screening, diagnosis and treatment of MASLD, and liver stiffness measurement as an important surrogate marker for liver-related outcomes in MASLD.

Abstract Image

查看原文本刊更多论文

MASLD 的新疗法和最新临床实践指南

2024 年对于代谢功能障碍相关性脂肪性肝病（MASLD）来说意义重大：首款治疗高危代谢功能障碍相关性脂肪性肝炎的药物获得批准，MASLD 的筛查、诊断和治疗指南得到更新，肝硬度测量成为衡量 MASLD 肝脏相关结果的重要替代指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.